“…On the basis of multiple lines of evidence, soluble Aβ peptides are still regarded by many as key pathological species in AD, potentially contributing to both pathogenesis and disease progression (Hardy and Selkoe, ; Hardy and Higgins, ). Thus, in attempts to better understand the patho‐physiological mechanisms underlying AD, numerous studies focusing on the biological actions of acutely administered exogenous soluble Aβ peptides have been made both in vivo (An et al, ; Brouillette et al, ; Klyubin et al, ) and in vitro (Lambert et al, ; Lauren et al, ; Li et al, ; Minkeviciene et al, ; Parameshwaran et al, ; Puzzo et al, ; Wang et al, ). The other major approach to understanding Aβ biology focuses on the use of mouse lines transgenically engineered to overproduce Aβ peptide species, a model of more chronic exposure to Aβ species.…”